Mangubat, Angelito Carlo R.
HRN: 22-61-45 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/18/2023
CO-AMOXICLAV 625MG (TAB)
02/18/2023
02/25/2023
PO
625mg
Q8H
Fracture, Close, Complete, Tibia, R
Waiting Final Action
Indication: Empirical De-escalation Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes